Efficacy and Safety of Ziprasidone to Treat Depressive Symptoms in Patients With Schizophrenia

UnknownOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

March 31, 2012

Conditions
The Primary Evaluation is the Change From Baseline at End of Study for CDSS Total Scores.The Secondary Efficacy Evaluations Include: MADRS, PANSS Total Scores and Subscales and Responder Rate; CGI-S and CGI-I Scales.Safety Evaluations Include: Laboratory Test Abnormalities; BARS and SAS; Physical Examinations; Vital Signs; Electrocardiogram,Etc.Subjective Well-being Under Neuroleptics Short Form Will be Used in Our Study to Assess the Subjective Side-effects.
Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Peking University

OTHER

collaborator

Pfizer

INDUSTRY

lead

Wuhan University

OTHER

NCT01260116 - Efficacy and Safety of Ziprasidone to Treat Depressive Symptoms in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter